CNMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

366.88M

+6.05%

1.324

-1.23%

330.02M

+2.73%

0.953

+0.26%

351.98M

+2.81%

1.103

-4.13%

Estimates Revision

The market is revising No Change the revenue expectations for CONMED Corporation (CNMD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.55%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-23.55%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 53.50 USD with a low forecast of 52.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 40.320

Low

52.00

Averages

53.50

High

55.00

Current: 40.320

Low

52.00

Averages

53.50

High

55.00

BofA

Neutral

downgrade

$65 -> $52

2025-12-07

Reason

BofA

Price Target

$65 -> $52

2025-12-07

downgrade

Neutral

Reason

BofA lowered the firm's price target on Conmed to $52 from $65 and keeps a Neutral rating on the shares after the company said it will exit its gastroenterology product lines. The exit is accretive to gross margins but dilutive to earnings in 2026, the analyst tells investors in a research note.

Piper Sandler

Matt O'Brien

Overweight

downgrade

$68 -> $55

2025-11-06

Reason

Piper Sandler

Matt O'Brien

Price Target

$68 -> $55

2025-11-06

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Conmed to $55 from $68 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that were roughly in-line with its estimates on the top-and-bottom line. Management essentially kept its revenue guidance for the year unchanged but did lower EPS by three cents, Piper adds.

JPMorgan

Neutral

downgrade

$58 -> $52

2025-11-06

Reason

JPMorgan

Price Target

$58 -> $52

2025-11-06

downgrade

Neutral

Reason

JPMorgan lowered the firm's price target on Conmed to $52 from $58 and keeps a Neutral rating on the shares. The company reported a good Q3 amid "slow and steady" supply and execution improvements, the analyst tells investors in a research note.

Needham

Buy

Hold

downgrade

2025-06-12

Reason

Needham

Price Target

2025-06-12

downgrade

Buy

Hold

Reason

Needham downgraded Conmed to Hold from Buy without a price target. The company's long-term growth rate has decreased, mainly due to slower AirSeal and Buffalo Filter growth, the analyst tells investors in a research note. The firm believes the slower revenue growth is likely to drive more gradual margin improvement and slower earnings growth at Conmed. In addition, the company's debt level limits its ability to acquire new growth drivers or to repurchase shares, contends Needham. The firm says Conmed's outlook has deteriorated while the shares no longer at a discount given that peer multiples have contracted.

JP Morgan

Robbie Marcus

Buy

Hold

Downgrades

$85 → $70

2025-02-06

Reason

JP Morgan

Robbie Marcus

Price Target

$85 → $70

2025-02-06

Downgrades

Buy

Hold

Reason

Needham

Mike Matson

Strong Buy

Maintains

$97 → $91

2025-02-06

Reason

Needham

Mike Matson

Price Target

$97 → $91

2025-02-06

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Conmed Corp (CNMD.N) is 9.26, compared to its 5-year average forward P/E of 26.55. For a more detailed relative valuation and DCF analysis to assess Conmed Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

26.55

Current PE

9.26

Overvalued PE

37.64

Undervalued PE

15.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

15.64

Current EV/EBITDA

7.92

Overvalued EV/EBITDA

20.38

Undervalued EV/EBITDA

10.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.44

Current PS

0.91

Overvalued PS

3.37

Undervalued PS

1.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CNMD News & Events

Events Timeline

No data

News

2.0

12-09NASDAQ.COM

CONMED (CNMD) Experiences Oversold Conditions

8.5

12-08NASDAQ.COM

CONMED Shares Decline Following Strategic Withdrawal from Gastroenterology Portfolio

6.5

12-07Yahoo Finance

Examining CONMED's Story Following Adjustments in Analyst Models and Financial Strategies

People Also Watch

Frequently Asked Questions

What is Conmed Corp (CNMD) stock price today?

The current price of CNMD is 40.32 USD — it has decreased -1.25 % in the last trading day.

What is Conmed Corp (CNMD)'s business?

CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

What is the price predicton of CNMD Stock?

What is Conmed Corp (CNMD)'s revenue for the last quarter?

Conmed Corp revenue for the last quarter amounts to 337.93M USD, increased 6.70 % YoY.

What is Conmed Corp (CNMD)'s earnings per share (EPS) for the last quarter?

Conmed Corp. EPS for the last quarter amounts to 0.09 USD, decreased -94.27 % YoY.

What changes have occurred in the market's expectations for Conmed Corp (CNMD)'s fundamentals?

How many employees does Conmed Corp (CNMD). have?

Conmed Corp (CNMD) has 3900 emplpoyees as of December 16 2025.

What is Conmed Corp (CNMD) market cap?

Today CNMD has the market capitalization of 1.25B USD.